Wegovy Pill Gets FDA Nod: Oral Weight Loss Drug Set to Transform Market

• US FDA approves Novo Nordisk's oral Wegovy, a daily pill for weight loss containing semaglutide.
• The new pill, expected in January 2026, offers ~17% average weight loss, slightly higher than injectable Wegovy.
• While Eli Lilly's Mounjaro remains more potent (20-22% weight loss), Wegovy is the first oral GLP-1 on the market.
• Oral convenience could attract patients avoiding injections, intensifying competition in the $50 billion obesity drug market.
• Eli Lilly, Roche, and AstraZeneca are also developing oral GLP-1s, betting on ease of use for wider adoption.

Why It Matters: Oral Wegovy's FDA approval marks a major shift, prioritizing convenience in the booming weight-loss market.